Clinuvel Pharmaceuticals Ltd (CLVLF) stock

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Clinuvel Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Clinuvel Pharmaceuticals's price to sales ratio was 4.0× on Nov 3, 2026, against 6.0× a year earlier. Over the last 2 years it ranged from 4.0× to 8.4×, with a median of 6.3×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 3, 2026	4.0×	−3.0
2025	Dec 31, 2025	7.0×	+0.2
2024	Dec 31, 2024	6.8×	–

Where these numbers come from

Parsed from the XBRL in Clinuvel Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing